Advances in human genetics and plant biotechnology are transforming medicine. Within the decade, biopharma may represent 35 percent of a $5 billion-a-year pharmaceutical market. Plant-based production of valuable Active Pharmaceutical Ingredients (API) such as proteins and phytochemicals can lead the way to new drugs without the ethical and technical drawbacks of mammalian transgenic production, or the inherent limitations of yeast-based fermentation systems.
SubTerra LLC has proven its plant based API productions methods. In a collaborative research project we have successfully scaled up production of seeds from transgenic tobacco plants engineered to express a glycoprotein used in cancer research.